• Policy
• Budget increase for drugs and vaccines under NA review
• by Lee, Jeong-Hwan Nov 17, 2022 05:54am

• Opinion
• [Reporter's view] Generic drugs can't be me-too drug
• by Kim, Jin-Gu Nov 17, 2022 05:54am

• InterView
• “Amgen addresses all unmet needs regardless of indication”
• by Eo, Yun-Ho Nov 17, 2022 05:54am

• Company
• Generic companies won 9 out of 10 patent disputes
• by Kim, Jin-Gu Nov 17, 2022 05:54am

• Company
• Announcement of commercialization of oral insulin
• by Eo, Yun-Ho Nov 17, 2022 05:54am

• Company
• The aftermath of stricter generic regulations?
• by Kim, Jin-Gu Nov 16, 2022 06:11am

• Company
• Gavreto applies for reimbursement following Retevmo
• by Eo, Yun-Ho Nov 16, 2022 06:10am

• Policy
• Use of Evusheld extended to the severely immunocompromised
• by Kim, Jung-Ju Nov 16, 2022 06:10am

• Company
• Impinzi's indication of biliary tract cancer
• by Nov 16, 2022 06:10am

• Opinion
• [Reporter's view] APAP price increase should be quick
• by Lee, Tak-Sun Nov 16, 2022 06:10am